GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TOWA Pharmaceutical Co Ltd (TSE:4553) » Definitions » EBIT

TOWA Pharmaceutical Co (TSE:4553) EBIT : 円25,406 Mil (TTM As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is TOWA Pharmaceutical Co EBIT?

TOWA Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was 円7,160 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was 円25,406 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TOWA Pharmaceutical Co's annualized ROC % for the quarter that ended in Dec. 2023 was 4.61%. TOWA Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 11.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TOWA Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 8.07%.


TOWA Pharmaceutical Co EBIT Historical Data

The historical data trend for TOWA Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TOWA Pharmaceutical Co EBIT Chart

TOWA Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20,840.00 18,918.00 22,476.00 5,240.00 25,406.00

TOWA Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 577.00 7,332.00 3,472.00 7,160.00 7,442.00

Competitive Comparison of TOWA Pharmaceutical Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, TOWA Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TOWA Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TOWA Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TOWA Pharmaceutical Co's EV-to-EBIT falls into.



TOWA Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円25,406 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TOWA Pharmaceutical Co  (TSE:4553) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TOWA Pharmaceutical Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=24808 * ( 1 - 33.81% )/( (349372 + 362543)/ 2 )
=16420.4152/355957.5
=4.61 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

TOWA Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=28640/( ( (133849 + max(118760, 0)) + (143679 + max(118097, 0)) )/ 2 )
=28640/( ( 252609 + 261776 )/ 2 )
=28640/257192.5
=11.14 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(53428 + 99805 + 21803) - (19587 + 0 + 36689)
=118760

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(59551 + 99667 + 23271) - (21441 + 0 + 42951)
=118097

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TOWA Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=25406/314952.213
=8.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TOWA Pharmaceutical Co EBIT Related Terms

Thank you for viewing the detailed overview of TOWA Pharmaceutical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


TOWA Pharmaceutical Co (TSE:4553) Business Description

Traded in Other Exchanges
Address
2-11, Shinbashi-cho, Kadoma, Osaka, JPN, 571-8580
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.

TOWA Pharmaceutical Co (TSE:4553) Headlines

No Headlines